MAJOR MARKET COMPARISON OF KEY COVID-19 LEGISLATION
As pharmaceutical companies worldwide race to supply vaccines
and therapeutics to fight the spread of COVID-19, understanding the
laws and regulations that could impact parties involved in the
COVID-19 pandemic supply chain is increasingly important. This
article provides an overview and comparison of legislation relevant
to manufacturers, suppliers, distributors, and health professionals
involved in the response to the COVID-19 pandemic in each of the
United States ( US ), European Union ( EU ),
United Kingdom ( UK ), and People s Republic of China
( PRC ), including measures to ensure (1) immunity from
COVID-19 countermeasure liability; (2) government ability to direct
(or redirect) resources; (3) emergency use authorizations; (4)
To print this article, all you need is to be registered or login on Mondaq.com.
On Friday, December 11, the U.S. Food and Drug Administration
issued the first emergency use authorization ( EUA ) for
a vaccine for the prevention of coronavirus disease 2019
( COVID-19 ) caused by severe acute respiratory syndrome
coronavirus 2 ( SARS-CoV-2 ) in individuals 16 years of
age and older. The EUA allows the Pfizer-BioNTech COVID-19 Vaccine
to be distributed in the U.S. and delivery to 145 hospitals,
clinics and public health systems in all 50 states has already
begun. While the distribution of the vaccine is subject to a
complex set of rules, we have highlighted below some key facts for